Swedish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

neurodegenerative diseases/hampor

Länken sparas på Urklipp
9 resultat

Cannabinoids for use in the treatment of neurodegenerative diseases or disorders

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
The present invention relates to cannabinoids for use in the prevention or treatment of neurodegenerative diseases or disorders. Preferably the cannabinoids are cannabichromene (CBC) cannabidivarin (CBDV) and/or cannabidivarin acid (CBDVA). More preferably the neurodegenerative disease or disorder

Non-psychotropic cannabinoids

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION The present invention relates to a family of novel non-psychotropic cannabinoids, and to pharmaceutical compositions containing them, which are useful for preventing or alleviating neurotoxicity and inflammation. Said pharmaceutical compositions comprise as their active

Non-psychotropic cannabinoids

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION The present invention relates to a family of novel non-psychotropic cannabinoids, and to pharmaceutical compositions containing them, which are useful for preventing or alleviating neurotoxicity and inflammation. Said pharmaceutical compositions comprise as their active

Use of known agonists of the central cannabinoid receptor CB1

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
The present invention relates to the use of known agonists of the central cannabinoid receptor CB1 for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma. .DELTA..sup.9 -Tetrahydrocannabinol (.DELTA..sup.9

Use of known agonists of the central cannabinoid receptor CB1

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
The present invention relates to the use of known agonists of the central cannabinoid receptor CB1 for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma. .DELTA..sup.9 -Tetrahydrocannabinol (.DELTA..sup.9

Vasodilator cannabinoid analogs

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION FIELD OF THE INVENTION The present invention relates to the discovery of novel ligands specific for a receptor from the cannabinoid (CB) receptor family. The invention discloses the discovery of novel ligands specific to this receptor that act as antagonists to the

Cannabinoid inhaler and composition therefor

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION The present invention relates to a cannabinoid inhaler and a composition therefor. BACKGROUND Cannabinoids have long been known for their therapeutic potential in pain relief, treatment of seizures, antiemesis et cetera. It is, however, a class of compounds whose usage has

Cannabinoids as antioxidants and neuroprotectants

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION The present invention concerns pharmaceutical compounds and compositions that are useful as tissue protectants, such as neuroprotectants and cardioprotectants. The compounds and compositions may be used, for example, in the treatment of acute ischemic neurological insults or

Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
CROSS REFERENCE TO PRIOR APPLICATIONS This application is a U.S. national phase of International Application No. PCT/IB2006/001437 filed Jun. 1, 2006, which claims priority from Indian Patent Application No. 659/MUM/2005 filed on Jun. 2, 2005, U.S. Provisional Application No. 60/696,433, filed Jul.
Gå med på vår
facebook-sida

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen

  • Fungerar på 55 språk
  • Växtbaserade botemedel som stöds av vetenskap
  • Örter igenkänning av bild
  • Interaktiv GPS-karta - märka örter på plats (kommer snart)
  • Läs vetenskapliga publikationer relaterade till din sökning
  • Sök efter medicinska örter efter deras effekter
  • Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent

Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning

Google Play badgeApp Store badge